/
PSTV
$4.29+$0.09 (+2.14%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$28.9M
7M shares
52-week range
$2.90 – $23.43
7% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
100.96%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-918.21
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $7.0M | $303.0K | $0 | $224.0K | $4.9M | $5.8M | $5.2M |
| Cost of revenue | $1.1M | $0 | $2.7M | $66.0K | $712.0K | $9.7M | $852.0K | $445.0K |
| Gross profit | $1.8M | $7.0M | −$2.4M | −$66.0K | −$488.0K | −$4.8M | $5.0M | $4.8M |
| Gross margin | 61.5% | 100.0% | -791.1% | — | -217.9% | -97.2% | 85.4% | 91.5% |
| R&D | $5.5M | $5.4M | $3.5M | $5.3M | $9.7M | $9.7M | $10.6M | $8.4M |
| Operating income | −$8.8M | −$3.7M | −$9.6M | −$12.5M | −$19.7M | −$13.3M | −$14.7M | −$15.3M |
| EBITDA | −$6.6M | −$532.0K | −$8.4M | −$12.0M | −$18.9M | −$12.3M | −$8.4M | −$18.3M |
| Net income | −$12.6M | −$10.9M | −$8.2M | −$13.4M | −$20.3M | −$13.3M | −$13.0M | −$22.4M |
| Net margin | -423.5% | -155.6% | -2719.8% | — | -9051.3% | -271.0% | -222.8% | -429.4% |
| EPS (diluted) | -32617500.00 | -3452500.00 | -697500.00 | -444500.00 | -288750.00 | -106000.00 | -58.50 | -7.19 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-3.98 | $-3.99–$-3.97 | 3 |
| 2027 | $20M | $-2.36 | $-2.49–$-2.22 | 3 |
| 2028 | $46M | $-0.32 | $-0.62–$-0.05 | 3 |
| 2029 | $121M | $1.67 | $0.91–$2.52 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
PLUS THERAPEUTICS, Inc. Common Stock
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
www.plustherapeutics.com- Employees
- 28
- IPO / List date
- Nov 16, 2000
- HQ
- AUSTIN, TX
Held by traders on TradeandTell
No one on the platform currently holds PSTV.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PSTV as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-04-02 | 1-for-25reverse |
| 2023-05-01 | 1-for-15reverse |
| 2019-08-06 | 1-for-50reverse |
| 2018-05-24 | 1-for-10reverse |
| 2016-05-12 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded PSTV yet.
